Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (11-20 of 119) with videos related to

Pageof 12
Sort By:
Methods (San Diego, Calif.)|July 16, 2013
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functionsChristian Kellner, Stefanie Derer, Thomas Valerius, et al.
Best Practice & Research. Clinical Haematology|June 11, 2011
Molecular engineering to improve antibodies' anti-lymphoma activityMatthias Peipp, Jan G J van de Winkel, Thomas Valerius
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2012
Fc engineering: design, expression, and functional characterization of antibody variants with improved effector functionStefanie Derer, Christian Kellner, Sven Berger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2014
Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loopThies Rösner, Stefan Lohse, Matthias Peipp, et al.
Archivum Immunologiae Et Therapiae Experimentalis|May 29, 2010
Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodiesStefan Lohse, Matthias Peipp, Thomas Beyer, et al.
Kidney & Blood Pressure Research|July 17, 2004
Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugsLutz Renders, Reiko Steinbach, Thomas Valerius, et al.
Critical Reviews in Immunology|June 19, 2014
Complement in antibody-based tumor therapyStefanie Derer, Frank J Beurskens, Thies Rosner, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 12, 2014
Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterizationStefanie Derer, Christian Kellner, Thies Rösner, et al.
Frontiers in Immunology|September 30, 2022
Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?Chilam Chan, Marta Lustig, Niklas Baumann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 11, 2003
Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cellsBernhard Stockmeyer, Thomas Beyer, Winfried Neuhuber, et al.
Pageof 12

Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Methods (San Diego, Calif.)|July 16, 2013
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functionsChristian Kellner, Stefanie Derer, Thomas Valerius, et al.
Best Practice & Research. Clinical Haematology|June 11, 2011
Molecular engineering to improve antibodies' anti-lymphoma activityMatthias Peipp, Jan G J van de Winkel, Thomas Valerius
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2012
Fc engineering: design, expression, and functional characterization of antibody variants with improved effector functionStefanie Derer, Christian Kellner, Sven Berger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2014
Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loopThies Rösner, Stefan Lohse, Matthias Peipp, et al.
Archivum Immunologiae Et Therapiae Experimentalis|May 29, 2010
Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodiesStefan Lohse, Matthias Peipp, Thomas Beyer, et al.
Kidney & Blood Pressure Research|July 17, 2004
Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugsLutz Renders, Reiko Steinbach, Thomas Valerius, et al.
Critical Reviews in Immunology|June 19, 2014
Complement in antibody-based tumor therapyStefanie Derer, Frank J Beurskens, Thies Rosner, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 12, 2014
Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterizationStefanie Derer, Christian Kellner, Thies Rösner, et al.
Frontiers in Immunology|September 30, 2022
Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?Chilam Chan, Marta Lustig, Niklas Baumann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 11, 2003
Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cellsBernhard Stockmeyer, Thomas Beyer, Winfried Neuhuber, et al.
Pageof 12